Schizophrenia

At each acute presentation, determine whether suicidal behavior, persistent aggressive behavior, inability to maintain safety, or recurrent relapse is driving the episode. Persistent substantial suicide-attempt or suicide risk despite other treatments is a specific circumstance in which clozapine is recommended; the same applies to substantial persistent aggressive behavior despite other treatments.Nature+1NatureEfficacy and safety of clozapine in psychotic disorders—a systematic quantitative meta-review | Translational PsychiatryPubMedClozapine - StatPearls - NCBI Bookshelf

Reassess the longitudinal diagnosis when the course becomes affective, substance-related, medically atypical, or inconsistent with prior episodes. First-episode psychosis diagnoses are usually stable within the schizophrenia spectrum (pooled stability 0.93, 95% CI 0.89-0.97), but about 5% transition to an affective-spectrum psychosis; ongoing diagnostic review therefore changes treatment planning when mood syndromes become syndromically prominent.Oxford AcademicOxford AcademicDiagnostic Stability of ICD/DSM First Episode Psychosis ...

Document a baseline symptom and function measure that can be repeated after each treatment change. PANSS is a standardized 30-item clinician-rated measure of general schizophrenia symptoms; pair symptom tracking with direct assessment of medication exposure, adverse effects, suicidality, substance use, and functional deterioration rather than interpreting persistent psychosis as drug failure alone.cdn clinicaltrials+1cdn clinicaltrialsOvercoming psychomotor slowing in psychosis (OCoPS-P) - A 3 ...NatureEffectiveness of antipsychotic medication in patients with schizophrenia in a real world retrospective observational study in Ethiopia | Scientific Reports

For nonrefractory schizophrenia, use a prior effective and tolerated agent when available. When selecting a new agent, weigh expected efficacy against the patient’s history of metabolic dysregulation, extrapyramidal symptoms, hyperprolactinemia, cardiovascular risk, medication acceptability, preferred formulation, comorbid illness, and prior response. Outside clozapine in refractory illness, sufficiently large and consistent efficacy differences among antipsychotics are not established; adverse-event differences often drive the practical choice.ScienceDirectScienceDirectFrom receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics - ScienceDirect

Consider a long-acting injectable antipsychotic when missed oral doses, recurrent relapse, uncertain exposure, or patient preference makes sustained oral treatment unreliable. Long-acting injectable strategies can improve adherence and reduce relapse, but they do not remove the need to evaluate metabolic, motor, and endocrine adverse effects.Nature+1NatureNature Index Antipsychotic Treatment Strategies in SchizophreniaWolters KluwerDifferentiating aspects of oral and long-acting injectable ...

Do not equate a second-generation antipsychotic with low cardiometabolic risk. Antipsychotics, particularly second-generation agents, are associated with metabolic dysregulation, cardiovascular adverse effects, and type 2 diabetes risk. Olanzapine may precipitate metabolic syndrome early in treatment, whereas clozapine carries substantial long-term metabolic burden; treatment selection should therefore incorporate baseline physical risk and the feasibility of ongoing monitoring.ScienceDirect+1ScienceDirectComparing the pharmacology and pharmacokinetics of antipsychotics: Choosing an antipsychotic and dosing a long-acting injectableScienceDirectThe association of metabolic syndrome and long acting injectable ...

When psychosis persists, reconstruct each prior antipsychotic trial before assigning treatment resistance: agent, dose trajectory, treatment duration, adherence, formulation, adverse effects, relapse timing, and reason for discontinuation. Pharmacologically informed, measurement-based prescribing integrates acute symptom goals with long-term functional goals and reduces the risk of misclassifying inadequate exposure or an intolerable regimen as pharmacologic failure.ScienceDirectScienceDirectFrom receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics - ScienceDirect

A recurrent pattern of missed medication, inconsistent follow-up, or relapse after stopping oral treatment should lead first to an adherence-focused intervention, including a long-acting injectable option when acceptable. Sustained antipsychotic therapy significantly reduces relapse risk after first-episode psychosis, although published discontinuation relapse estimates vary widely across studies.PubMedPubMedPrevalence of treatment resistance and clozapine use in early intervention services - PMC

If persistent symptoms occur despite adequate prior antipsychotic treatment and adherence has been addressed, treat the patient as having likely treatment-resistant schizophrenia and evaluate for clozapine. Clozapine remains the gold-standard treatment in treatment-resistant schizophrenia and is the only antipsychotic with regulatory approval for this indication.The Lancet+3The LancetClozapine and treatment-resistant schizophrenia: efficacy ...WileyClozapine: past, present and future - Correll - 2025 - World PsychiatryPubMedClozapine - StatPearls - NCBI BookshelfPubMedPrevalence of treatment resistance and clozapine use in early intervention services - PMC

Offer clozapine for treatment-resistant schizophrenia after confirming that persistent illness is not principally due to nonadherence, inadequate prior exposure, or a revised diagnosis. Compared with other dopamine receptor-blocking antipsychotics in treatment-resistant schizophrenia, clozapine has demonstrated superior positive-symptom reduction and advantages in relapse or hospitalization, suicidal behaviors, aggressive behavior, substance use, functioning, and mortality outcomes.WileyWileyClozapine: past, present and future - Correll - 2025 - World Psychiatry

Discuss clozapine earlier rather than framing it as a last resort. Up to 40% of patients may meet treatment-resistant schizophrenia criteria, yet clozapine is prescribed to fewer than 10% of people with schizophrenia worldwide; delayed use is associated with reduced efficacy.WileyWileyClozapine: past, present and future - Correll - 2025 - World Psychiatry

Before and during initiation, plan the monitoring infrastructure rather than relying on patient recall. Clozapine requires hematologic examinations, and therapeutic drug level monitoring may sometimes be needed. Its adverse-effect burden includes potentially life-threatening myocarditis, reported particularly in the first 8 weeks, as well as metabolic toxicity; these risks justify structured surveillance and rapid assessment of compatible symptoms.ScienceDirect+2ScienceDirectComparing the pharmacology and pharmacokinetics of antipsychotics: Choosing an antipsychotic and dosing a long-acting injectableWileyClozapine: past, present and future - Correll - 2025 - World PsychiatryPubMedClozapine - StatPearls - NCBI Bookshelf

Schedule follow-up around the individual’s relapse pattern and treatment delivery route. At each visit, record current psychotic symptoms, negative symptoms when relevant, functional change, medication exposure, adverse effects, suicidal thinking, substance use, and hospital or emergency utilization. PANSS can quantify overall symptom change, while the Brief Negative Symptom Scale assesses domains such as apathy and diminished expression when negative symptoms are a treatment target.cdn clinicaltrialscdn clinicaltrialsOvercoming psychomotor slowing in psychosis (OCoPS-P) - A 3 ...

Treat physical-health surveillance as part of antipsychotic effectiveness, not as a separate preventive task. People with schizophrenia have an estimated 13- to 15-year shorter life expectancy than healthy controls, predominantly related to chronic physical conditions including coronary heart disease and type 2 diabetes. Monitor central obesity, dyslipidemia, glucose intolerance, and hypertension because they define metabolic syndrome and predict cardiovascular, diabetes, and cerebrovascular risk.ScienceDirectScienceDirectThe association of metabolic syndrome and long acting injectable ...

When metabolic toxicity, motor toxicity, or poor adherence threatens persistence, revise the regimen before relapse occurs. A switch to a lower metabolic-risk option, a long-acting injectable to improve exposure continuity, or clozapine for genuine treatment resistance should be selected according to the driver of treatment failure rather than a uniform escalation sequence.Nature+3NatureNature Index Antipsychotic Treatment Strategies in SchizophreniaScienceDirectFrom receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics - ScienceDirectWileyClozapine: past, present and future - Correll - 2025 - World PsychiatryScienceDirectThe association of metabolic syndrome and long acting injectable antipsychotics: A systematic review